Angle Share Price (AGL)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Angle Plc	LSE:AGL	London	Ordinary Share	GB0034330679	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.50p	-1.15%	43.00p	168,881	13:07:59

Bid Price		Offer Price	High Price	Low Price	Open Price
42.00p		44.00p	43.50p	42.50p	43.50p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Support Services	0.63	-8.93	-10.09		61.3

Related Shares
Experian (EXPN), Ferguson (FERG), Kellan Group (KLN), Nakama (NAK)

Angle (AGL) Latest News

Angle News

Date	Time	Source	Headline
09/10/2018	07:00	UKREG	Angle PLC Notice of AGM
28/8/2018	14:17	ALNC	Angle's Parsortix System Able To Identify Tumour Cells In Glioblastoma
28/8/2018	08:15	ALNCF	Alliance News Flash Headline
28/8/2018	07:01	RNSNON	Angle PLC Parsortix shows evidence of CTCs in glioblastoma
25/7/2018	12:26	ALNC	Angle Annual Loss Widens As It Progresses Parsortix Regulatory Tests
25/7/2018	07:00	UKREG	Angle PLC Preliminary Results for year ended 30 April 2018
24/7/2018	17:42	UKREG	Angle PLC EIS/VCT Advance Assurance and Total Voting Rights
18/7/2018	10:34	UKREG	Angle PLC Result of General Meeting
02/7/2018	07:00	UKREG	Angle PLC Notice of Preliminary Results
25/6/2018	18:34	ALNC	UPDATE: ANGLE Raises GBP12.7 Million Through Share Placing (ALLISS)

More Angle News

Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date	Time	Title	Posts
19/10/2018	21:28	ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET	10,255
28/8/2018	12:29	ANGLE plc (AGL) One to Watch	-
02/7/2018	12:06	Still time to look at Angle (AGL)	-
14/5/2018	09:44	ANGLE (AGL) Strategic Move	-
16/3/2017	20:00	ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."	3,646

Add a New Thread

Angle (AGL) Most Recent Trades

No Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type

View all Angle trades in real-time

Angle (AGL) Top Chat Posts

Date	Subject
21/10/2018 09:20	Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 43.50p. Angle Plc has a 4 week average price of 42p and a 12 week average price of 42p. The 1 year high share price is 60.50p while the 1 year low share price is currently 37.50p. There are currently 142,486,522 shares in issue and the average daily traded volume is 64,961 shares. The market capitalisation of Angle Plc is £61,269,204.46. Read Full Thread Reply
23/8/2018 18:49	andypar: I'm a huge fan of AGL. Simple, high margin, high barriers to entry. Here are a few of my thoughts. Dilution hell or screening heaven ? Are the collaborations already in place all set up for FDA approval,so the moment we get it then the revenue can start kicking in ? I don't want to be reading a year after FDA that they are trying to establish sales channels etc. If the revenue does not ramp up very quickly then there will be more shares issued and we will be back to the famous AIM story of Jam Tomorrow. The big $$$ takeover that we all hope for will only occur from a position of strength ie sales and a strong balance sheet. Otherwise we will be diluted into oblivion and maybe saved at the last by a takeover on the cheap. With our current cost base we need approx. $15m in revenue to breakeven. We need at least $5m in sales the year following FDA and it to double year on year thereafter. I want everything ready to go and all the trumpets blaring when we get FDA. If the share price doubles or triples post FDA approval do another capital raise then for say $25m (hopefully the last). Don't forget we will need to fund further trials to get approval from the FDA for other cancers. This should be considerably less arduous than it has been for the MBC. Also post FDA approval I want AGL start talking about blood test screening. That would put the share price into orbit (also less dilution etc). Big pharma and the city could not fail to see the potential $$$$$$. A trial of 100 apparently fit people over 65 to see if they could pick up CTC's in any of the subjects. If the trial gave positive results ie picked up CTC's in say 5 of the subjects and led to potentially earlier diagnnosis and treatment. It would add a lot of $$$$$ to the market cap, even if real life screening was still 10 years away. It is much easier to talk about a market cap of billions when AGL talks screening :o) Everyone understands screening and the potential $$$$$$$$$$$$$$. AGL would be mad once we have to FDA approval not to exploit this. Get the market cap up, get us off AIM. Put us in the shop window as the future of medicine. Read Full Thread Follow Reply
22/8/2018 17:47	mikepompeyfan: In the absence of significant buying market makers lower a share price to drum up buying interest. They make their money on the spread so do all they can to generate turnover. They don't care at what share price. As a news driven share the price will soon be up again when it comes. Read Full Thread Follow Reply
21/8/2018 16:32	alloa2003: In the research stage it must be hard for medical/drug companies. They need to keep shareholders happy in the short term when really they should be focusing on the long term and not lose sight of long term goals. AGL is doing everything right but the share price is not reflecting this YET - I appreciate the market wants certainty which I think they will get in due course. If the company gets FDA clearance I think AGL will be one of those shares which goes crazy over a few days. Read Full Thread Follow Reply
25/7/2018 19:47	alloa2003: Hi MorganK, I have said this a few times now, I think the risk reward ratio comparing the share price to the possible price if FDA approval is gained is very much on the side of caution. The gap is just too big as we approach make or break bearing in mind what we already know. It must be a great arbitrage situation for those who work purely on the risk/reward ratio. I too believe we will see the share price gradually rise in anticipation. Read Full Thread Follow Reply
24/7/2018 19:00	alloa2003: Longterm, I cannot get my head around why so many people are concerned about dilution. If the product does anywhere near what the company expects then the share price will be a multiple of what it is now. We are not talking about a company selling clothing, food or shoes, we are talking about a one product company which is actually a sh*t hot or bust investment. I can see what you might mean about the second placing but what do you want the company to do? Wait until further down the line when they need more money and more importantly the market knows they need more money. This is when the vultures hover, sell short and push the price down and down increasing the dilution. You could argue the management was behind the ball and slow to react with the first placing but the second placing is simply a case of raising money when you can, when maybe you dont need it immediately. But it does take away any potential funding issues in the short to medium term. As far as the first placing goes, without this there would be no company. So it is beyond me why people still complain about dilution with the rescue fund raising when in reality there would have been no company without it. Also, when a small company is trying to raise a decent amount of money there will always be significant dilution simply because of the size of the company. Quite how you expect the company to "resolve" the dilution issues is beyond me. I think some people get mixed up between the idea of dilution and actual existance. If the share price doubles, trebles or more then personally I could not give a hoot about dilution. Read Full Thread Follow Reply
09/7/2018 11:25	jelenko: The question is how much would we charge for a license? I think good trial results and the share price would start to factor in FDA approval. Remember how quickly it raced to 79p on the Bart's prostate news last year. This time the magnitude of the rise would be greater, I think we all know that. I have a simple way of looking at the share price potential especially when we have a meaningful revenue number( at some future date) Every £10m in revenue @75% margin and 15 PE would equate to 79p share price. Every £100m in revenue £790p. The market is enormous and you would think that with FDA £100m should be easily attainable. Especially when the market size the company talks about is valued in £bilions. Read Full Thread Follow Reply
09/5/2018 12:49	bones698: Waterloo nice to see some sense on here for a change . We both agree the potential is there my view is though will agl deliver . I also have concerns that in other countries where they have received the required approval that no sales are being generated years after they received them which begs the question why aren't fast they taking up parasotix if it's so good ???? The sales agreements seem to be delivering nothing again this is concerning and the pace agl moves at seems to point to a lot more money needing to be raised to get to the point of a profit if they ever get there . I have seen many potential market making inventions come and go without ever getting close and unfortunately I see the same thing here if I'm honest . To me the share price isn't warranted and should still be hovering around the right price until progress is shown on any front . The cash they raised is being eaten into at a fair rate of knots so it won't be long before that scenario comes round again to haunt shareholders . Remember they will savage the share price prior to any mention as the city gets wind of them needing cash just like last time only next will be even worse . Read Full Thread Follow Reply
26/3/2018 09:17	alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off. Read Full Thread Follow Reply
24/12/2017 11:06	alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :) Read Full Thread Follow Reply
11/6/2017 15:55	alloa2003: Personally I think if AGL had taken this slowly slowly approach a couple of years ago the share price would be much higher. We have suffered from mismanagement of expectations but hopefully the BOD have learnt a lesson. Let the results come through and let them speak for themselves. Trying to guess when the FDA might act on AGL's application(s) is a waste of time but good trial results will put more pressure on the FDA. Share price targets of £5 are unrealistic at this moment in time but we could have a game changing year and a rejuvenated share price. First of all we need to see constant positive news flow and better management of expectations. The recent research note suggesting a share price of 187p (from memory) seems ambitious but achievable in this very volatile area in which AGL operates. One of the other keys is to maximise the current benefits of Parsortix over competing system asap - that way we get a foothold in the market. Once we are there, the companies who operate in this area will not be changing their systems every 2 minutes and only then will we see the sales flow that everyone has been hoping for. Read Full Thread Follow Reply

Angle share price data is direct from the London Stock Exchange

add chat code

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:31 V: D:20181021 15:42:06